ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Oncology and Hematology News and Journal Articles

Optimizing the Delivery of Antineoplastic Therapies to the Central Nervous System

This review describes the anatomy of the blood-brain barrier and currently available methods to quantify the entry of therapeutic compounds into the brain. It also summarizes data from a variety of approaches designed to improve drug delivery to the central nervous system.

Recent Content

This interview examines the role of functional imaging to direct therapy (escalation or de-escalation) for early and advanced Hodgkin lymphoma.

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy significantly increased response rates among women with BRCA1 or BRCA2 mutations and locally recurrent or metastatic breast cancer, according to a randomized phase II trial.

In this video we discuss longer term results of the phase III SABRINA study, which tested the safety and efficacy of subcutaneous rituximab in patients with follicular lymphoma.

Treatment with buparlisib in combination with endocrine therapy significantly improved PFS compared with placebo in patients with HR-positive advanced breast cancer that had progressed after treatment with everolimus plus exemestane.

The addition of estrogen deprivation to neoadjuvant chemotherapy did not significantly affect pathologic complete response in women with HR-positive, HER2-positive breast cancer.

In this interview we discuss the use of liquid biopsies in lung cancer, the pros and cons compared with tissue biopsies, and how they can be used to help make treatment decisions.

The PD-L1 inhibitor atezolizumab significantly improved overall survival compared with docetaxel across subgroups of patients with non–small-cell lung cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.